Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,071,056
  • Shares Outstanding, K 1,636,700
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.18
  • Price/Sales 4.84
  • Price/Cash Flow 20.45
  • Price/Book 6.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.42 +4.09%
on 01/16/18
63.22 -2.17%
on 01/12/18
-0.56 (-0.90%)
since 12/15/17
3-Month
59.42 +4.09%
on 01/16/18
64.99 -4.83%
on 10/20/17
-2.33 (-3.63%)
since 10/17/17
52-Week
46.01 +34.43%
on 01/26/17
66.10 -6.43%
on 10/13/17
+5.57 (+9.90%)
since 01/17/17

Most Recent Stories

More News
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug

Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.

EXEL : 27.49 (-7.28%)
RHHBY : 30.4500 (-0.75%)
PFE : 37.18 (+1.58%)
BMY : 61.85 (+3.22%)
Today's Research Reports on Stocks to Watch: Bristol-Myers Squibb Company and Merck & Co.

NEW YORK, NY / ACCESSWIRE / January 17, 2017 / Merck shares soared on Tuesday while shares of rival company Bristol-Myers hit negative territory on news that Merck's Keytruda drug had positive results...

MRK : 62.03 (-0.06%)
BMY : 61.85 (+3.22%)
Bristol-Myer Sqb Falls 3.74% on Heavy Volume: Watch For Potential Rebound

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $60.30 to a high of $61.86. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $61.18...

BMY : 61.85 (+3.22%)
SmarTrend Watching for Potential Rebound in Shares of Bristol-Myer Sqb After 3.74% Loss

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $60.30 to a high of $61.86. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $61.18...

BMY : 61.85 (+3.22%)
Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating...

LPTX : 6.22 (+1.47%)
BMY : 61.85 (+3.22%)
Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

NVO : 56.41 (+1.99%)
JNJ : 146.98 (+0.08%)
MRK : 62.03 (-0.06%)
PFE : 37.18 (+1.58%)
GSK : 38.15 (+0.61%)
SNY : 44.60 (-0.69%)
BMY : 61.85 (+3.22%)
Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference

Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.

CELG : 102.02 (-2.67%)
MRK : 62.03 (-0.06%)
PFE : 37.18 (+1.58%)
BMY : 61.85 (+3.22%)
PD-1/PD-L1 Inhibitors Market Report 2017: Sales of the PD-1/PD-L1 Therapy Class have Grown from $84m in 2014 to $6,292m in 2016

The "PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology" report has been added to Research and Markets' offering.

BMY : 61.85 (+3.22%)
Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial

Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.

EXEL : 27.49 (-7.28%)
RHHBY : 30.4500 (-0.75%)
PFE : 37.18 (+1.58%)
BMY : 61.85 (+3.22%)
Seattle Genetics' Adcetris sBLA Gets FDA Priority Review

Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.

SCMP : 18.00 (-0.28%)
MRK : 62.03 (-0.06%)
SGEN : 52.56 (+3.16%)
BMY : 61.85 (+3.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human...

See More

Key Turning Points

2nd Resistance Point 63.10
1st Resistance Point 62.47
Last Price 61.85
1st Support Level 60.75
2nd Support Level 59.66

See More

52-Week High 66.10
Last Price 61.85
Fibonacci 61.8% 58.43
Fibonacci 50% 56.06
Fibonacci 38.2% 53.68
52-Week Low 46.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.